Chi-Med Starts Phase I Trial of Cancer Drug in Australia

Hutchison China MediTech has dosed its initial patient in a first-in-human Phase I clinical trial of HMPL-689. The trial is being conducted in Australia. HMPL-689 is a novel small molecule inhibitor of the B-cell receptor signaling pathway, intended to treat B-cell cancers and autoimmune diseases. With this latest test underway, Chi-Med now has 24 trials involving seven novel drug candidates in progress. More details.... Stock Symbol: (NSDQ/AIM: HCM) Share this with colleagues: // //